The "Biologics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Recent studies highlight breakthroughs in medical treatments. A novel monoclonal antibody cocktail has shown promise in ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Adding a monoclonal antibody cocktail to the standard treatment for inoperable liver cancer nearly doubled the amount of time ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Treatment for HER2-positive breast cancer depends on tumor size and spread but may involve a combination of chemotherapy, targeted therapy, monoclonal antibody therapy, and kinase inhibitors.